> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Revised Guide on Inspections During Covid
- URL: https://www.fdaweb.com/revised-guide-on-inspections-during-covid/
- Published: 2021-05-17T12:00:00.000Z
- Updated: 2026-09-14T16:59:10.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5149332

FDA has posted a [revised guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/manufacturing-supply-chain-and-drug-and-biological-product-inspections-during-covid-19-public-health?ref=fdaweb.com) entitled *Manufacturing, Supply Chain, and Drug and Biological Product Inspections During Covid-19 Public Health Emergency — Questions and Answers*. The revision answers questions about regulatory and policy issues related to inspections, pending drug applications, and changes in manufacturing facilities for approved pharmaceutical products. The document updates a guidance of the same title issued in 8/2020 August 2020, and revised in January.

The guidance also discusses review decisions impacted by delayed inspections. For example, a complete response letter will be issued if available information from a prior inspection or other source identifies deficiencies about a facility or site and the required inspection cannot be completed due to factors including travel restrictions. If an inspection is necessary because there is a lack of information about the facility or site but cannot be completed due to factors including travel restrictions, a complete response letter will be issued but the facility or site deficiency will not be issued in such cases (the facility or site issue will be a comment in the letter), FDA says.